Previous 10 | Next 10 |
– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury, fibrosis and lipids – – Pegozafermin has the poten...
89bio press release ( NASDAQ: ETNB ): Q3 GAAP EPS of -$0.57 beats by $0.26 . As of September 30, 2022, 89bio had cash, cash equivalents, and short-term investments of $193.3 million For further details see: 89bio GAAP EPS of -$0.57 beats by $0.26
-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of pegozafermin at AASLD The Liver Meeting ® 2022- -Reported additio...
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously rep...
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...
Summary 89bio's share price is up >100% over the past three months. The company is developing Pegozafermin, a potential therapy for NASH and SHTG. Data released by Akero for its drug Efruxifermin - which has the same mechanism of action as Pego - suggested it would meet the...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...
SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company’s Ma...
89bio ( NASDAQ: ETNB ) stock rose ~9% premarket Aug. 26 after the company presented data from a phase 2 trial of pegozafermin to treat severe hypertriglyceridemia (SHTG) at the European Society of Cardiology (ESC) Congress 2022. SHTG is a condition in which there is ...
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Ph...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...